Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

Corrie, P.G., Marshall, A., Nathan, P.D. et al. (36 more authors) (2018) Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Annals of Oncology.

Abstract

Metadata

Authors/Creators:
  • Corrie, P.G.
  • Marshall, A.
  • Nathan, P.D.
  • Lorigan, P.
  • Gore, M.
  • Tahir, S.
  • Faust, G.
  • Kelly, C.G.
  • Marples, M.
  • Danson, S.J. https://orcid.org/0000-0002-3593-2890
  • Marshall, E.
  • Houston, S.J.
  • Board, R.E.
  • Waterston, A.M.
  • Nobes, J.P.
  • Harries, M.
  • Kumar, S.
  • Goodman, A.
  • Dalgleish, A.
  • Martin-Clavijo, A.
  • Westwell, S.
  • Casasola, R.
  • Chao, D.
  • Maraveyas, A.
  • Patel, P.M.
  • Ottensmeier, C.H.
  • Farrugia, D.
  • Humphreys, A.
  • Eccles, B.
  • Young, G.
  • Barker, E.O.
  • Harman, C.
  • Weiss, M.
  • Myers, K.A.
  • Chhabra, A.
  • Rodwell, S.H.
  • Dunn, J.A.
  • Middleton, M.R.
  • AVAST-M Investigators, .
Copyright, Publisher and Additional Information: © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: melanoma; bevacizumab; adjuvant therapy
Dates:
  • Published: 13 July 2018
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 16 Aug 2018 08:59
Last Modified: 16 Aug 2018 08:59
Published Version: https://doi.org/10.1093/annonc/mdy229
Status: Published online
Publisher: Oxford University Press
Refereed: Yes
Identification Number: https://doi.org/10.1093/annonc/mdy229
Related URLs:

Download

Share / Export

Statistics